NICE confirms positive guidance on use of Galafold (migalastat) to treat Fabry disease.- Amicus Therapeutics
The National Institute for Health and Care Excellence (NICE) has confirmed final guidance endorsing the use of Galafold (migalastat) from Amicus Therapeutics to treat the 855 patients in the UK with Fabry disease, an inherited Lysomal Storage disease. The price of Galafold (prior to any agreed discounts) is £210,000 per patient per annum for life of the patient. The recommendation applies to patients over 16 years of age with an amenable mutation, but subject to the discount agreed in a patient access scheme and only if enzyme replacement therapy (ERT) would otherwise be offered.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.